Trabectedin in advanced soft tissue sarcoma: case series
Demirci, U.; Buyukberber, S.; Yetisyigit, T.; Dizdar, O.; Benekli, M.; Alkis, N.; Coskun, U.
Journal of BUON Official Journal of the Balkan Union of Oncology 17(3): 591-592
2012
ISSN/ISBN: 1107-0625 PMID: 23033305 Document Number: 663546
The prognosis of advanced soft tissue sarcomas (STS) is poor. The median overall survival (OS) is 6 months in unresectable and metastatic STS that progress after treatment with anthracyclines and ifosfamide. Trabectedin is an alkylating agent, effective in advanced STS, especially in leiomyosarcoma and liposarcoma. In the present study, the effectiveness and safety of trabectedin was retrospectively evaluated in 8 unresectable and metastatic STS patients. Their median age was 47 years. The median progression free survival (PFS) was 3.75 months and the median OS 15 months in relapse or progression after anthracyclines and/or ifosfamide. Toxicities were mainly hematologic. In the present study, trabectedin showed efficacy in different histological subtypes of sarcomas like liposarcoma and leiomyosarcoma.